Pembrolizumab: tested on its own

368 studies: no other medicine in its arm. Page 1 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast CancerNot yet recruitingNCT07857486Phase 2Report a problem
• Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07689240Phase 3Report a problem
• A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.RecruitingNCT07448831Phase 2Report a problem
• Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)Not yet recruitingNCT07388550Phase 1Report a problem
• Neoadjuvant Pembrolizumab in Patients With Stage IIb/c MelanomaRecruitingNCT07349303Phase 2Report a problem
• A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)RecruitingNCT07302347Phase 1/2Report a problem
• Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerRecruitingNCT07251582Phase 3Report a problem
• Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast CancerRecruitingNCT07188246Phase 2Report a problem
• A Study of Pembrolizumab in People With Ultra-Rare SarcomasRecruitingNCT07089992Phase 2Report a problem
• Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialRecruitingNCT07061964Phase 2Report a problem
• Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaRecruitingNCT07007273Phase 2Report a problem
• Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin LymphomaNot yet recruitingNCT06916416Phase 2Report a problem
• Circadian Rhythm Impact on TNBC Response to Neoadjuvant ImmunotherapyRecruitingNCT06880029Phase 1/2Report a problem
• Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical AdenocarcinomaNot yet recruitingNCT06805864Phase 2Report a problem
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingNCT06770582Phase 2Report a problem
• Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and ChemotherapyNot yet recruitingNCT06691594Phase 2Report a problem
• Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.RecruitingNCT06670911Phase 2Report a problem
• Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 2Report a problem
• Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesRecruitingNCT06640283Phase 2Report a problem
• Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast CancerRecruitingNCT06606730Phase 3Report a problem
• OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd TrialRecruitingNCT06558214Phase 2Report a problem
• Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast CancerRecruitingNCT06472583Phase 2Report a problem
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2Report a problem
• A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy AdultsRecruitingNCT06173011Phase 1Report a problem
• Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant TherapyNot yet recruitingNCT06146777Phase 3Report a problem
• European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]RecruitingNCT06137378Phase 2Report a problem
• Study of Radiotherapy and Pembrolizumab in People With Adrenocortical CarcinomaRecruitingNCT06066333Phase 2Report a problem
• Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2Report a problem
• A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)RecruitingNCT06004336Phase 2Report a problem
• Pembrolizumab in High-risk Thyroid CancerRecruitingNCT05852223Phase 2Report a problem
• Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabRecruitingNCT05812807Phase 3Report a problem
• A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic NeoplasiaRecruitingNCT05635344Phase 2Report a problem
• Pembrolizumab for Advanced NSCLC and PS 2-3RecruitingNCT05589818Phase 2Report a problem
• Pembrolizumab Plus Radiotherapy for Advanced Renal CancerRecruitingNCT05567588Phase 2Report a problem
• Neoadjuvant PD-1 Blockade in Resectable Merkel Cell CarcinomaRecruitingNCT05496036Phase 2Report a problem
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKRecruitingNCT05266846Phase 2Report a problem
• The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With PembrolizumabRecruitingNCT05235737Phase 4Report a problem
• Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder CancerRecruitingNCT05072600Phase 2Report a problem
• Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell CarcinomaRecruitingNCT05025813Phase 2Report a problem
• NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell CarcinomaRecruitingNCT05024318Phase 2Report a problem
• Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaRecruitingNCT04977375Phase 1/2Report a problem
• SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical ProstatectomyRecruitingNCT04931979Phase 2Report a problem
• Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLCRecruitingNCT04909684Phase 3Report a problem
• Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2Report a problem
• Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck CancerRecruitingNCT04754321Phase 1Report a problem
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT04671667Phase 2Report a problem
• Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer PatientsRecruitingNCT04375956Phase 2Report a problem
• Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmRecruitingNCT04317534Phase 2Report a problem
• Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2RecruitingNCT04297605Phase 1Report a problem
• Checkpoint Inhibition In Pediatric Hepatocellular CarcinomaRecruitingNCT04134559Phase 2Report a problem
• Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal CancerRecruitingNCT04109755Phase 2Report a problem
• Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast CancerRecruitingNCT03971045Phase 2Report a problem
• Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLCRecruitingNCT03769129Not applicableReport a problem
• Pembrolizumab in Treating Participants With LeukoplakiaRecruitingNCT03603223Phase 2Report a problem
• Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck CancerRecruitingNCT03532737Phase 2Report a problem
• Trial of Pembrolizumab in Metastatic Castration Resistant Prostate CancerRecruitingNCT03506997Phase 2Report a problem
• Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsRecruitingNCT03449238Phase 1/2Report a problem
• Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic CancerRecruitingNCT03295227Phase 1Report a problem
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/2Report a problem
• Study of Combined Decompressive Spine Radiosurgery and PembrolizumabTerminatedNCT05204290Early Phase 1Results postedReport a problem
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesTerminatedNCT05191472Phase 2Results postedReport a problem
• Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerActive, not recruitingNCT05119296Phase 2Results postedReport a problem
• IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATCTerminatedNCT05059470Phase 2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)CompletedNCT04875195Phase 2Results postedReport a problem
• Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)Active, not recruitingNCT04808999Phase 2Results postedReport a problem
• Quad Shot Radiotherapy in Combination With Immune Checkpoint InhibitionCompletedNCT04454489Phase 2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)CompletedNCT04317066Phase 1Results postedReport a problem
• Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural MesotheliomaTerminatedNCT04166734Phase 1Results postedReport a problem
• Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)CompletedNCT04098068Phase 2Results postedReport a problem
• Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal AdenocarcinomaTerminatedNCT04089904Phase 2Results postedReport a problem
• Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid CancersCompletedNCT04082572Phase 2Results postedReport a problem
• Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung CancerActive, not recruitingNCT04032418Phase 2Results postedReport a problem
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)TerminatedNCT03990961Phase 2Results postedReport a problem
• Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell CarcinomaTerminatedNCT03988647Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Phase 3Results postedReport a problem
• Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)TerminatedNCT03924869Phase 3Results postedReport a problem
• Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Phase 3Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension StudyCompletedNCT03850444Phase 3Results postedReport a problem
• Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)TerminatedNCT03833167Phase 3Results postedReport a problem
• Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of EsophagusCompletedNCT03792347Phase 1Results postedReport a problem
• Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)CompletedNCT03783078Phase 3Results postedReport a problem
• Trial of Pembrolizumab in Cancer of Unknown PrimaryCompletedNCT03752333Phase 2Results postedReport a problem
• NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal CancerActive, not recruitingNCT03734809Phase 2Results postedReport a problem
• Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeActive, not recruitingNCT03728972Phase 2Results postedReport a problem
• Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)CompletedNCT03715205Phase 4Results postedReport a problem
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk MelanomaActive, not recruitingNCT03698019Phase 2Results postedReport a problem
• Pembrolizumab in Treating Patients With Stage IB-IV Mycosis FungoidesCompletedNCT03695471Phase 2Results postedReport a problem
• Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung StudyCompletedNCT03634241Phase 2Results postedReport a problem
• Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)Active, not recruitingNCT03553836Phase 3Results postedReport a problem
• Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLCCompletedNCT03526887Phase 2Results postedReport a problem
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative DiseasesTerminatedNCT03498612Phase 2Results postedReport a problem
• Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial CarcinomaTerminatedNCT03486197Phase 2Results postedReport a problem
• Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT03430700Phase 2Results postedReport a problem
• Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityActive, not recruitingNCT03428802Phase 2Results postedReport a problem
• A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell CancerCompletedNCT03425565Phase 2Results postedReport a problem
• Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown PrimaryTerminatedNCT03396471Phase 2Results postedReport a problem
• Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)CompletedNCT03391973Phase 2Results postedReport a problem
• A Single Dose of Pembrolizumab in HIV-Infected PeopleTerminatedNCT03367754Phase 1Results postedReport a problem
• Breast Cancer Study of Preoperative Pembrolizumab + RadiationActive, not recruitingNCT03366844Phase 1/2Results postedReport a problem
• Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue SarcomaCompletedNCT03338959Phase 1/2Results postedReport a problem

← Pembrolizumab